Biomarker-targeted adjuvant therapy improved survival in early-stage NSCLC, highlighting the importance of testing and ...

Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma.

What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous ...

KRAS is the most common oncogenic driver in non-squamous NSCLC, found to be mutated in 25% to 30% of patients. Sotorasib is a ...

Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

A new kind of cancer treatment is emerging—one that turns the patient’s own body into a drug factory. Here's what you need to ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...

Christopher Danes, PhD, discusses how patient and caregiver priorities and concerns vary during the course of treatment for non–small cell lung cancer.